https://clinicaltrials.gov/study/NCT06385509
Study Overview
Brief Summary
TOL-CLAR-20024 is a Phase 4, multi-center, open-label safety study evaluating the potential effect of JATENZO on adrenal function in hypogonadal men treated with JATENZO for 12 months.
Detailed Description
Following...